ZEISS Vision Care announces investment in Ocumeda amid plans to scale the leading tele-ophthalmology platform with Fielmann Group

ZEISS Vision Care, an internationally leading technology company in the eye and vision care industry, announced today that it has signed a definitive agreement to acquire a 10% stake in Ocumeda AG (“Ocumeda”) from Fielmann Group for €10m, with the intention to acquire up to a 25% stake. The transaction values Ocumeda at €100m.

Sven Hermann, President and CEO of ZEISS Consumer Markets and Member of the Executive Board of the ZEISS Group: “Our investment in Ocumeda is part of our commitment to protect and improve the vision and visual health of consumers. We want to strengthen accessible eye and vision care – in Ocumeda we have found an excellent partner for this mission. A partner who shares our high standards in innovation and quality. Ocumeda already plays an important role as a future-proof platform provider for the ZEISS EyeCare Network, giving our customers the possibility to be successful in a business area with high potential and significant impact on consumers.”

“At ZEISS Medical Technology, central to our mission is the advancement of medical progress through innovative technologies and workflows. An important pillar of that progress is helping to make eye and vision care more accessible. ZEISS Vision Care’s investment in Ocumeda underscores this strong commitment to innovation and accessibility”, says Maximilian Foerst, President and CEO of ZEISS Medical Technology and Member of the Executive Board of the ZEISS Group.

Marc Fielmann, CEO of Fielmann Group: “We are excited to welcome ZEISS Vision Care as a strategic investor in Ocumeda. Together, we look forward to expanding Europe’s leading tele-ophthalmology platform as an open resource for patients, opticians, optometrists and ophthalmologists. This partnership marks an important milestone in Fielmann Group’s Vision 2035 growth strategy, which aims to make primary eyecare accessible and affordable. This way we pursue our purpose – to help everyone hear and see the beauty in the world.”

Benedikt Wiechers, CEO and Founder of Ocumeda: “This investment is another important step forward in our mission to prevent vision loss for millions of people. ZEISS Vision Care’s commitment to innovation and excellence perfectly aligns with our own values. Building on the strong foundation we created with Fielmann, ZEISS Vision Care will empower us to accelerate the expansion of our network of opticians, optometrists, and ophthalmologists into further markets and address the growing global shortage in accessible eye care."

about fielmann group ag
The Fielmann Group is a stock-listed German family business active in vision care and audiology, serving 30m customers with eyewear, contact lenses, primary eyecare services and hearing aids. As one of the leading vision care providers worldwide, it operates an omnichannel platform consisting of digital sales channels and more than 1,200 stores in Europe and the United States. Founded in 1972, the company is led by Marc Fielmann, representing the second generation of the Fielmann family, which still owns the majority of the company’s stock. By staying true to its customer-centric values, the Fielmann Group helps everyone hear and see the beauty in the world. Thanks to the dedication of its more than 24,000 people worldwide, the company consistently achieves customer satisfaction and retention rates of around 90% and has fitted more than 200m pairs of individual prescription glasses.

about OCUMEDA AG
Ocumeda is the leading tele-ophthalmology platform in Europe. It’s mission: preventing vision loss and blindness for millions of people. The company was founded by an interdisciplinary team around renowned ophthalmologists, who were repeatedly confronted with patients with serious eye diseases that were in many cases diagnosed too late – with the consequence that vision loss was no longer avoidable. This observation was the impetus for founding Ocumeda, with the aim of making eye care accessible for everyone. To date, Ocumeda has already examined about 300.000 patients with its network of over 700 optical retail stores and ophthalmologists across Europe.

about ZEISS
ZEISS is an internationally leading technology company in the optics and optoelectronics industry. The ZEISS Group generated annual revenue totalling around 11 billion euros in its four segments Industrial Quality & Research, Medical Technology, Consumer Markets and Semiconductor Manufacturing Technology (as of 30 September 2024). For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.  With more than 46,555 employees, ZEISS operates in around 50 countries with more than 60 sales and service sites, 40 research and development sites and 35 production sites worldwide (as of 31 March 2025).
ZEISS Vision Care is one of the world's leading manufacturers of eyeglass lenses and ophthalmic instruments. The unit is allocated to the Consumer Markets segment and develops and produces offerings for the entire eyeglass value chain that are distributed globally under the ZEISS brand. More information: www.zeiss.com